Use of recombinant factor Vlla for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis

Yulia Lin; Stanworth, Simon; Birchall, Janet; Doree, Carolyn; Hyde, Christopher
January 2011
CMAJ: Canadian Medical Association Journal;1/11/2011, Vol. 183 Issue 1, p55
Academic Journal
Background: The benefits and risks of off- label use of recombinant factor Vila in patients without hemophilia are contested. We performed a systematic review to assess the effectiveness and safety of such use. Methods: We searched electronic databases including MEDLINE, EMBASE and CENTRAL for randomized controlled trials comparing recombinant factor Vila with placebo in any patient population except those with hemophilia up to January 2010. Eligible articles were assessed for inclusion, data were extracted, and study quality was evaluated. Outcomes included mortality, blood loss, requirements for red blood cell transfusion, number of patients transfused and thromboembolic events. Results: We identified 26 trials: 14 on off-label prophylactic use of recombinant factor Vila (n = 1137) and 12 on off-label therapeutic use (n = 2538). In the studies on prophylactic use, we found no significant difference in mortality or thromboembolic events between the treatment and placebo groups. We found modest benefits favouring recombinant factor Vila in blood loss (weighted mean difference -276 mL, 95% confidence interval [CI] -411 to -141 mL), red blood cell transfusion (weighted mean difference -281 mL, 95% CI -433 to -129 mL) and number of patients transfused (relative risk 0.71, 95% CI 0.50 to 0.99). In the therapeutic trials, we found a nonsignificant decrease in mortality and a nonsignificant increase in thromboembolic events but no difference in control of bleeding or red blood cell transfusion. Interpretation: Clinically significant benefits of recombinant factor Vila as a general hemosta- tic agent in patients without hemophilia remain unproven. Given its potential risks, such use cannot be recommended, and in most cases, it should be restricted to clinical trials.


Related Articles

  • The development of psychological support for the Wales Inherited Bleeding Disorder service. Kelly, Lynne // Clinical Psychology Forum;May2015, Issue 269, p3 

    The article offers the author's insights regarding the development of psychological support for patients with haemophilia, a group of inherited bleeding disorders, in Wales. Topics discussed include several treatments, such as whole blood transfusions and cryoprecipitation, gaps in haemophilia...

  • Biovitrum, Biogen Idec Eye 2011 Filing for Recombinant Factor IX. Sheridan, Cormac // BioWorld International;10/21/2009, Vol. 14 Issue 42, p1 

    The article reports on the plan of Biovitrum AB and Biogen Idec Inc. to use their long-acting Factor IX Fc fusion protein (rFIXFc) in a registration trial in hemophilia B patient in the first quarter of 2010. The disease is hereditary and caused by mutations in the gene encoding coagulation...

  • Factors influencing the adoption of blood alternatives to minimizing allogenic transfusion: the perspective of eight Ontario hospitals. Graham, Ian D.; Alvarez, Gonzalo; Tetroe, Jacqueline; McAuley, Laura; Laupacis, Andreas // Canadian Journal of Surgery;Apr2002, Vol. 45 Issue 2, p132 

    Identifies the factors influencing the adoption of blood alternatives to minimize allogeneic transfusion in Ontario. Use of cell salvage devices, hemostatic agents and erythropoietin; Perception of the safety of allogeneic blood; Promotion of blood-sparing methods.

  • Prophylaxis in Patients with Severe Hemophilia and Inhibitor. Jimenez-Yuste, Victor; Alvarez, Maria Teresa; Martin-Salces, Monica; Rodriguez-Merchan, E. Carlos; Butta, Nora; Fernandez-Bello, Ihosvany; Rivas, Isabel; Rodriguez de la Rua, Ana // Journal of Coagulation Disorders;2009, Vol. 1 Issue 1, p1 

    Joint hemorrhage, the most common manifestation of severe hemophilia, frequently leads to recurrent hemarthrosis, chronic synovitis, and arthropathy. The main goal of replacement therapy is to prevent this pathology. On-demand treatment slows, but does not prevent, the progression of...

  • Factor VIII Inhibitor Assays: Methodology, Shortcomings, and Challenges. van Geffen, M.; Dardikh, M.; Verbruggen, B. // Journal of Coagulation Disorders;2010, Vol. 2 Issue 2, p1 

    Development of inhibitory antibodies against factor VIII is a serious complication in the treatment of hemophilia patients, as these antibodies inactivate factor VIII, resulting in an increased bleeding tendency and morbidity. The clinical manifestation of inhibitors has to be analyzed by...

  • Prophylactic Factor Infusions for Patients with Hemophilia: Challenges with Treatment Adherence. Thornburg, Courtney D. // Journal of Coagulation Disorders;2010, Vol. 2 Issue 2, p1 

    Prophylaxis to prevent chronic arthropathy is recommended for all patients with severe hemophilia. However, effective implementation can be hampered by poor adherence with prescribed infusions. Reported adherence with prophylaxis has been excellent in the Joint Outcomes Study and in several...

  • Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A. Shin Young Hyun; Seon Yang Park; Soon Yong Lee; Hoon Kook; Sang Hoon Paik; In-Jin Jang; Kun Soo Lee // Yonsei Medical Journal;Jul2015, Vol. 56 Issue 4, p934 

    Purpose: Beroctocog alfa is a second generation recombinant factor VIII manufactured by removing the B-domain from factor VIII. This prospective clinical trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of beroctocog alfa in patients of ages ≥ 12 years previously...

  • Cryoprecipitate Concentrates of Factor VIII for Surgery in Hemophiliacs. Cooke, Jeremy V.; Holland, Paul V.; Shuman, N. Raphael // Annals of Internal Medicine;Jan68, Vol. 68 Issue 1, p39 

    Presents a study that compared the effectiveness of cryoprecipitate with that of Merck FIBRO-AHF and plasma in treating hemophiliacs undergoing surgery. Storage and preparation of cryoprecipitate for use; Characteristics of the cryoprecipitate; Comparison of in vitro yield and in vivo recovery...

  • Cognitive and psychological profiles in treatment compliance: a study in an elderly population with hemophilia. Riva, Silvia; Nobili, Alessandro; Djade, Codjo D.; Mancuso, Maria Elisa; Santagostino, Elena; Pravettoni, Gabriella // Clinical Interventions in Aging;Jul2015, Vol. 10, p1141 

    Elderly patients with hemophilia have to face new challenges linked to concomitant pathologies and concurrent use of different treatments. In order to promote optimal care in the elderly hemophilia population, this study is aimed to analyze treatment compliance in relation to the presence of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics